Navigation Links
Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team
Date:12/18/2013

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced the addition of Ronald G. Jubin, Ph.D. to their executive team as Managing Director, Research and Development. In his new role, Dr. Jubin will be responsible for pre-clinical discovery, methods development and the advancement of Prolong's pipeline candidates.

(Logo:  http://photos.prnewswire.com/prnh/20130926/NY87531LOGO )

"Ron brings more than two decades of experience at the forefront of drug discovery to our efforts here at Prolong," said Dr. Abraham Abuchowski, Prolong's Chief Scientific Officer and CEO. "We are excited to bring him on board at this important time in our company history." In October, Prolong presented Phase I data for its flagship product SANGUINATE an intravenous therapeutic that combines the beneficial functions of a carbon monoxide releasing molecule with an oxygen transfer agent as well as acting as a plasma expander. SANGUINATE was found to be well tolerated with no serious adverse events, and is now moving forward into Phase II trials in patients with sickle cell disease who suffer from painful vaso-occlusive crises. 

Dr. Jubin's experience includes key roles at Schering-Plough Research Institute and PBL Biomedical labs. At Schering-Plough, he served in major roles in the hepatitis C protease program, directed other HCV inhibitor programs and managed internal committees evaluating novel interferon candidate licensing opportunities. At PBL Biomedical, his tenure leading the R&D department at PBL resulted in the development of numerous interferon proteins
'/>"/>

SOURCE Prolong Pharmaceuticals LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
2. Prolong TM, a New Revolutionary First Line Treatment for Premature Ejaculation is Licensed in Europe
3. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... 12, 2011 If you could learn that you have a ... and 75 percent of that chance could be altered by lifestyle ... of the nation,s leading online direct-to-consumer online lab test and health ... Your Number HealthScore as seen on The Biggest Loser ...
... 2011 Urologists for Patient Access to Care (UPAC) ... men should no longer receive prostate-specific antigen (PSA) blood ... major retrenchment in preventive health care." Dr. ... health care advocates to speak out to preserve prostate ...
Cached Medicine Technology:PersonaLabs and BioSignia Join to Offer Targeted Risk Assessment 2Cancer Detection Tool Saves Lives 2
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Buying a ... an adult who is unsure about available coverage types by ... providing principal life insurance policy pricing to the public using ... use of this tool is free and is expected to ... available to the public throughout the U.S. The system is ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an increase in ... drug use among teenagers. The treatment facility aims to help ... to minimize drug abuse. , America is currently seeing some ... history. According to the National Institute of Drug Abuse ... or older—or 9.2 percent of the population—had used an illicit ...
(Date:8/22/2014)... Norton HealthDay Reporter ... number of Americans on work disability chronically use powerful ... found that between 2007 and 2011, about 44 percent ... prescribed narcotic painkillers each year. And the percentage using ... to 23 percent in 2011. Experts said ...
(Date:8/22/2014)... -- Many Americans know little about how Ebola is transmitted ... in the United States, a new survey shows. About ... will be a major Ebola outbreak in the United States, ... member will get sick with the deadly virus in the ... Health poll. However, those opinions don,t match reality, the ...
Breaking Medicine News(10 mins):Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2
... turn out to be an important therapeutic target besides ... like uterus and prostate tissues. ,These new ... of estrogen in breast cancer and point the way ... disease. ,The new study was published this ...
... in on a transporter that actually quietens the body’s ... for potent and non-habit //forming pain killers and will ... ,Opioid peptides are natural pain relievers with receptors ... throughout the body, says Dr. Vadivel Ganapathy, chair of ...
... on the manner of T-cells enabling immunity and furthering chances ... go a long way in measuring the efficiency of AIDS ... ,Led by researchers at Beth Israel Deaconess Medical Center ... Institute of Allergy and Infectious Diseases (NIAID), part of the ...
... in public health for the rest of the country and ... Singh Barnala said today. // ,'Several medical colleges, ... to the success of the health care industry in the ... and the quality and commitment of our doctors had gained ...
... of Health and Family Welfare Anbumani Ramadoss Friday urged ... endorsing //soft drinks in the larger interest of public ... golden jubilee celebrations of the Central Food Laboratory (CFL) ... safety and regulatory mechanism to protect the vast population ...
... According to the researchers at the Harvard Medical School it ... lungs of chronically infected cystic fibrosis (CF) patients. // Pseudomonas ... disease in the CF patients says Joseph Mougous, lead author ... Science. ‘In the case of Pseudomonas aeruginosa, the host may ...
Cached Medicine News:Health News:Functional Differences In Estrogen Receptor Could Be A Therapeutic Target 2Health News:Functional Differences In Estrogen Receptor Could Be A Therapeutic Target 3Health News:Transporter offers reliable clues for safer pain medicine 2Health News:Transporter offers reliable clues for safer pain medicine 3Health News:Research on AIDS vaccine a wealth of information 2Health News:Research on AIDS vaccine a wealth of information 3Health News:Treatment of Bacterial Infection Paves the Way to Treat CF Infection 2
The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
... importance of electronic connectivity for ... understood. Transmission of patient results ... records, and billing. A sound ... connectivity is essential to ensure ...
348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
248 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
Medicine Products: